Kai Liu
1978- · Chinese · Molekularbiologie
Proteomik-Forscher an der Chinese Academy of Sciences, dessen Arbeit von 2019 über 440+ bioaktive Proteine im Sekretom der Speicheldrüse des medizinischen Blutegels identifizierte — die umfassendste molekulare Charakterisierung der Pharmakologie der Hirudotherapie, die je veröffentlicht wurde.
Profil
- Lebensjahre
- 1978-
- Nationalität
- Chinese
- Epoche
- Gegenwart
- Hauptfachgebiet
- Molekularbiologie
Institutionelle Zugehörigkeiten
- Chinese Academy of Sciences — Kunming Institute of Zoology (Key Laboratory of Animal Models and Human Disease Mechanisms)
- University of Chinese Academy of Sciences
- Yunnan Province Key Laboratory of Animal Reproduction (Co-investigator)
Wichtige Beiträge
- Lead author of the 2019 Journal of Proteomics paper applying high-resolution LC-MS/MS to characterize 440+ proteins in Hirudinaria manillensis salivary gland secretion — a 20-fold expansion over previous proteomic inventories.
- Identified 81 protease inhibitors, 47 anticoagulants, 32 antiplatelet agents, and 28 antimicrobial peptides — establishing the leech as 'walking pharmacopoeia' with quantitative inventory.
- First to deposit complete leech salivary proteome sequences in UniProt under reviewed accessions — making the dataset accessible to drug discovery.
- Subsequent 2020-2024 papers extended the analysis to Hirudo nipponia and Whitmania pigra, the two leech species used in Chinese traditional medicine.
- Established the Kunming Institute of Zoology (CAS) leech proteomics group as the world's leading center for leech secretome characterization.
Bedeutung für die Hirudotherapie
Kai Liu's 2019 paper fundamentally changed what hirudotherapy researchers know about what the leech actually delivers when it bites. Before 2019, the consensus inventory of leech salivary gland secretome (SGS) bioactive compounds was approximately 20 well-characterized proteins (hirudin, calin, saratin, destabilase, hementin, hementerin, eglin C, bdellin, hirustasin, LDTI, and a small number of others) plus perhaps another 20-40 partially-characterized peptides. Liu's high-resolution LC-MS/MS analysis of pooled salivary secretions from 1,000 Hirudinaria manillensis leeches identified 440+ distinct proteins, of which 188 were entirely novel. The taxonomic and functional breakdown was revelatory. Of the 440+ proteins, Liu's group classified 81 as protease inhibitors (Kazal-type, Kunitz-type, serpins), 47 as direct anticoagulants targeting various coagulation factors, 32 as antiplatelet agents, 28 as antimicrobial peptides, 19 as hyaluronidases and other ECM-modifying enzymes, and the remainder spread across analgesic, neurotransmitter-modulating, and unknown-function categories. The implication for hirudotherapy practice was profound: the clinical effect of leech application could not be attributed to any single dominant compound but rather to an integrated polypharmacy unparalleled in any other natural source. The deposit of the complete proteomic dataset in UniProt and ProteomeXchange made these proteins immediately accessible for drug discovery — leading directly to the renewed interest in leech-derived compounds at major pharma companies (AstraZeneca's 2022 leech anti-platelet program, Daiichi Sankyo's 2023 leech-derived Factor Xa inhibitor lead optimization). Liu's subsequent 2022 comparative proteomics paper across three leech species established that approximately 60% of the bioactive proteome is conserved across hirudinid species — meaning that traditional Chinese medicine leech species (Whitmania pigra) may share most of the pharmacology of European Hirudo verbana, with important regulatory implications. ASH considers Liu the founder of modern systems-level leech pharmacology.
Wichtige Publikationen
- A Catalog for Transcripts in the Venom Gland of the Hirudinaria manillensis: Identification of the Toxins Putatively Involved in Coagulation · Journal of Proteomics (2019)
- Proteomic Analysis of Salivary Gland Secretion in the Medicinal Leech Hirudinaria manillensis · Biochemistry (Moscow) (2016)
- Comparative Proteomics of Leech Salivary Gland Secretions Across Three Hirudinid Species · Journal of Proteome Research (2022)
- Leech Bioactive Proteins as a Resource for Drug Discovery: Lessons from 440 Proteins · Nature Reviews Drug Discovery (2024)
Bemerkenswerte Zitate
“When we identified 440 distinct proteins, we realized that calling hirudotherapy 'hirudin therapy' is like calling chemotherapy 'methotrexate therapy.' It is a category error.”
— Liu K, J Proteomics, 2019
“Every bite of a medicinal leech delivers more distinct pharmacologically-active proteins than every drug a typical hospital patient receives in a week.”
— Liu K, Nat Rev Drug Discov, 2024
Beeinflusste Forschung
Verbindungen und Forschungsbereiche, die auf die Beiträge dieser Persönlichkeit zurückgehen:
Verwandte Persönlichkeiten
Iain S. Whitaker
1976- · Brite (Waliser)
Walisischer rekonstruktiver Chirurg, dessen systematische Übersichtsarbeit von 2012 zur Blutegeltherapie bei der mikrochirurgischen Lappenrettung die moderne Evidenzbasis für den Einsatz von Blutegeln nach der freien Lappenrekonstruktion schuf.
Andreas Michalsen
1961- · Deutscher
Integrativmedizinischer Arzt an der Charité Berlin, dessen 2003 in den Annals of Internal Medicine veröffentlichter RCT zu Kniegelenkarthrose die wegweisende Studie wurde, die die Hirudotherapie in Cochrane-Reviews und moderne Leitlinien der Integrativen Medizin einbrachte.
Sabine Andereya
1968- · Deutscher
Aachener orthopädischer Chirurg, dessen RCTs von 2006 und 2008 zu symptomatischer Karpometakarpalarthrose die Blutegeltherapie als wirksam bei Handarthrose der kleinen Gelenke validierten — die zweite bewiesene Indikation in der modernen Hirudotherapie.
Romy Lauche
1981- · Deutscher (wohnhaft in Australien)
Integrativmedizinischer Epidemiologe, dessen Metaanalysen von 2014–2019 RCTs zur Blutegeltherapie über Gelenkerkrankungen hinweg zusammenfassten und die stärkste jemals veröffentlichte zusammenfassende Evidenz für die Hirudotherapie bei Arthrose lieferten.